Document is current
Any future updates will be listed below
-
Authors
Kawamoto, Yasuharu
Yamai, Takuo
Ikezawa, Kenji
Seiki, Yusuke
Watsuji, Ko
Hirao, Takeru
Urabe, Makiko
Kai, Yugo
Takada, Ryoji
Mukai, Kaori
Nakabori, Tasuku
Uehara, Hiroyuki
Inoue, Tazuko
Fujisawa, Fumie
Ohkawa, Kazuyoshi
- License Information
-
More Information
Article History
Received: 10 February 2024
Accepted: 29 July 2024
First Online: 12 August 2024
Declarations
:
: This study conformed to the Declaration of Helsinki guidelines and was approved by the Ethical Review Committee of the Osaka International Cancer Institute (Approval number: 20148-3). Due to the retrospective nature of this study, the requirement for informed consent and consent to participate was waived using the opt-out method on our website. A waiver of informed consent was granted by the Institutional Review Board of Osaka International Cancer Institute.
: Not applicable.
: Yamai reports honoraria for lectures from Taiho Pharmaceutical and Yakult Honsha. Ikezawa reports honoraria for lectures from Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, MSD, Myriad Genetics, ASAHI KASEI PHARMA, Nihon Servier, AstraZeneca and Incyte Biosciences Japan, and research funding from ASKA Pharmaceutical. Takada reports honoraria for lectures from Taiho Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Myriad Genetics and TEIJIN PHARMA. Ohkawa reports honoraria for lectures from Eisai, Chugai Pharmaceutical, Yakult Honsha, Incyte Biosciences Japan, Takeda, Gilead, AstraZeneca and Hisamitsu, and research grants from Towa Pharmaceutical and Sumitomo Chemical. The other authors have no conflict of interest.
